Fennec Pharmaceuticals (TSE:FRX) Hits New 52-Week Low – Time to Sell?

by · The Cerbat Gem

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s stock price hit a new 52-week low on Monday . The stock traded as low as C$5.70 and last traded at C$5.70, with a volume of 1219 shares trading hands. The stock had previously closed at C$5.98.

Fennec Pharmaceuticals Stock Down 1.5 %

The company has a market cap of C$161.15 million, a price-to-earnings ratio of 59.80 and a beta of 0.25. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The firm’s fifty day simple moving average is C$6.61 and its 200 day simple moving average is C$8.37.

Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) EPS for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The business had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. Sell-side analysts predict that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current year.

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Featured Articles